In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...
With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class rare disease drug DIAG723. The Massachusetts-based biotech, which develops ...
Joel Levinson was in his second year of architecture studies at the University of Pennsylvania when he overheard two students speaking as if they were up to no good. These being fellow building buffs, ...
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 ...
WATERTOWN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe ...
Over the last decade, officials have tried a series of steps to rein in cars on Los Angeles streets. They turned parking spaces into micro-parks, converted street corners into trendy plazas and ...
Diagonal chops engage multiple muscle groups, particularly the obliques and rectus abdominis. This engagement strengthens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results